Avis Budget Group, Inc. logo

Avis Budget Group, Inc. (CAR)

Market Open
21 Jul, 17:13
NASDAQ (NGS) NASDAQ (NGS)
$
161. 56
+2.04
+1.2801%
$
5.64B Market Cap
4.27 P/E Ratio
40% Div Yield
93,511 Volume
39.99 Eps
$ 159.52
Previous Close
Add Transaction
Day Range
158.22 162.82
Year Range
85.96 847.7
Want to track CAR and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
CAR Group Limited (CSXXY) Shareholder/Analyst Call Transcript

CAR Group Limited (CSXXY) Shareholder/Analyst Call Transcript

CAR Group Limited (OTCPK:CSXXY) Shareholder/Analyst Call October 30, 2025 8:01 PM EDT Company Participants Patrick Redmond O'Sullivan William Elliot - MD, CEO & Director Nicole Birman - General Counsel & Company Secretary David Wiadrowski Edwina Gilbert Conference Call Participants Henry Stephens Conversation Patrick Redmond O'Sullivan Good morning, all, and welcome to the 2025 Annual General Meeting of CAR Group Limited. My name is Pat O'Sullivan, and I'm Chair of the company and Chair of this meeting.

Seekingalpha | 8 months ago
Ethic Inc. Acquires New Position in Avis Budget Group, Inc. $CAR

Ethic Inc. Acquires New Position in Avis Budget Group, Inc. $CAR

Ethic Inc. acquired a new stake in shares of Avis Budget Group, Inc. (NASDAQ: CAR) during the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 1,894 shares of the business services provider's stock, valued at approximately $330,000. Several other

Defenseworld | 8 months ago
Hemogenyx shares rise after safety board backs next trial phase for CAR-T therapy

Hemogenyx shares rise after safety board backs next trial phase for CAR-T therapy

Hemogenyx Pharmaceuticals PLC (LSE:HEMO, OTC:HOPHF) shares climbed as much as 8% in early trading after the biotech company said US regulators had cleared its experimental CAR-T therapy for leukaemia to move to a higher dose level in its ongoing Phase I trial. The independent Data Safety Monitoring Board, which oversees the study, reviewed safety data from the first three adult patients treated with Hemogenyx's HG-CT-1 therapy for relapsed or refractory acute myeloid leukaemia and found no dose-limiting toxicities.

Proactiveinvestors | 8 months ago
Avis Budget Group (CAR) Q3 Earnings and Revenues Top Estimates

Avis Budget Group (CAR) Q3 Earnings and Revenues Top Estimates

Avis Budget Group (CAR) came out with quarterly earnings of $10.11 per share, beating the Zacks Consensus Estimate of $8.11 per share. This compares to earnings of $6.65 per share a year ago.

Zacks | 8 months ago
Avis Budget Group Up 4% After Q3 Earnings: Here's Why

Avis Budget Group Up 4% After Q3 Earnings: Here's Why

Avis Budget Group (NASDAQ: CAR) delivered a sharp earnings surprise on Monday after the close, posting $10.11 in adjusted EPS that crushed consensus expectations of $8.12.

247wallst | 8 months ago
Hemogenyx rises on progress in CAR-T trial

Hemogenyx rises on progress in CAR-T trial

Hemogenyx Pharmaceuticals PLC (LSE:HEMO, OTC:HOPHF) shares jumped 26% after the biotech reported encouraging early results from its phase I trial of HG-CT-1, an experimental CAR-T therapy for relapsed or refractory acute myeloid leukaemia (AML). The London-listed company said its third patient had been treated successfully, with the therapy meeting initial safety targets and showing signs of efficacy.

Proactiveinvestors | 10 months ago
Avis Budget Stock Declines 22% Since Reporting Q2 Earnings Miss

Avis Budget Stock Declines 22% Since Reporting Q2 Earnings Miss

CAR plunges 22% after second-quarter 2025 earnings and revenues miss estimates despite a nearly 98% YTD surge in shares.

Zacks | 11 months ago
Avis Budget Group, Inc. (CAR) Q2 2025 Earnings Call Transcript

Avis Budget Group, Inc. (CAR) Q2 2025 Earnings Call Transcript

Avis Budget Group, Inc. (NASDAQ:CAR ) Q2 2025 Earnings Conference Call July 30, 2025 8:30 AM ET Company Participants Brian J. Choi - Chief Executive Officer David T.

Seekingalpha | 11 months ago
Avis Budget (CAR) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

Avis Budget (CAR) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

While the top- and bottom-line numbers for Avis Budget (CAR) give a sense of how the business performed in the quarter ended June 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Zacks | 11 months ago
Avis Budget Group (CAR) Misses Q2 Earnings and Revenue Estimates

Avis Budget Group (CAR) Misses Q2 Earnings and Revenue Estimates

Avis Budget Group (CAR) came out with quarterly earnings of $0.1 per share, missing the Zacks Consensus Estimate of $2.02 per share. This compares to earnings of $0.41 per share a year ago.

Zacks | 11 months ago
Waymo taps Avis to manage robotaxi fleet in Dallas

Waymo taps Avis to manage robotaxi fleet in Dallas

Waymo said it plans to launch a robotaxi service next year in Dallas, the latest city to be added to the Alphabet-owned company's growing commercial footprint that already includes Los Angeles and San Francisco.

Techcrunch | 11 months ago
Canadian Apartment REIT: More Upside After A Pause

Canadian Apartment REIT: More Upside After A Pause

We had upgraded Canadian Apartment REIT to a strong buy due to robust Q4 results and management's strategic actions. The stock has outperformed our shorter term expectations. We review the recent results and update our thesis.

Seekingalpha | 0 year ago
Loading...
Load More